Analyst Ratings For Fennec Pharmaceuticals (NASDAQ:FENC)
Today, HC Wainwright initiated coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy with a price target of $16.00.
Some recent analyst ratings include
- 2/20/2018-HC Wainwright initiated coverage with a Buy rating.
- 11/29/2017-Laidlaw initiated coverage with a Buy rating.
Recent Insider Trading Activity For Fennec Pharmaceuticals (NASDAQ:FENC)
Fennec Pharmaceuticals (NASDAQ:FENC) has insider ownership of 10.70% and institutional ownership of 38.22%.
- On 12/12/2017 Spa Essetifin, Major Shareholder, bought 294,115 with an average share price of $8.50 per share and the total transaction amounting to $2,499,977.50.
Recent Trading Activity for Fennec Pharmaceuticals (NASDAQ:FENC)
Shares of Fennec Pharmaceuticals closed the previous trading session at with 1237 shares trading hands.